Drug Profile
DP 001
Alternative Names: 2MD; DP-001; PF-00217763Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator University of Wisconsin-Madison
- Developer Deltanoid Pharmaceuticals
- Class Osteoporosis therapies; Small molecules; Vitamin D analogues
- Mechanism of Action Vitamin D3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Postmenopausal osteoporosis; Secondary hyperparathyroidism
Most Recent Events
- 28 Aug 2019 No recent reports on development identified - Phase-II for Secondary hyperparathyroidism in USA (PO)
- 08 Aug 2015 Phase II development for Secondary hyperparathyroidism is ongoing in the USA
- 08 Aug 2015 No recent reports of development identified - Phase-II for Postmenopausal osteoporosis in USA (PO)